| Literature DB >> 31639283 |
Lin Yang1,2,3, Regine Gradl4,5,6, Martin Dierolf4,5, Winfried Möller1,2, David Kutschke1,2, Annette Feuchtinger7, Lorenz Hehn4,8, Martin Donnelley9,10, Benedikt Günther4,5, Klaus Achterhold4,5, Axel Walch7, Tobias Stoeger1,2, Daniel Razansky3,11,12,13, Franz Pfeiffer4,5,6,8, Kaye S Morgan4,6,14, Otmar Schmid1,2.
Abstract
Targeted delivery of nanomedicine/nanoparticles (NM/NPs) to the site of disease (e.g., the tumor or lung injury) is of vital importance for improved therapeutic efficacy. Multimodal imaging platforms provide powerful tools for monitoring delivery and tissue distribution of drugs and NM/NPs. This study introduces a preclinical imaging platform combining X-ray (two modes) and fluorescence imaging (three modes) techniques for time-resolved in vivo and spatially resolved ex vivo visualization of mouse lungs during pulmonary NP delivery. Liquid mixtures of iodine (contrast agent for X-ray) and/or (nano)particles (X-ray absorbing and/or fluorescent) are delivered to different regions of the lung via intratracheal instillation, nasal aspiration, and ventilator-assisted aerosol inhalation. It is demonstrated that in vivo propagation-based phase-contrast X-ray imaging elucidates the dynamic process of pulmonary NP delivery, while ex vivo fluorescence imaging (e.g., tissue-cleared light sheet fluorescence microscopy) reveals the quantitative 3D drug/particle distribution throughout the entire lung with cellular resolution. The novel and complementary information from this imaging platform unveils the dynamics and mechanisms of pulmonary NM/NP delivery and deposition for each of the delivery routes, which provides guidance on optimizing pulmonary delivery techniques and novel-designed NM for targeting and efficacy.Entities:
Keywords: X-ray imaging; aerosol inhalation therapy; lung fluorescence imaging; optical tissue clearing; pulmonary delivery
Year: 2019 PMID: 31639283 DOI: 10.1002/smll.201904112
Source DB: PubMed Journal: Small ISSN: 1613-6810 Impact factor: 13.281